Cargando…
SBRT for centrally localized NSCLC – What is too central?
PURPOSE: Current guidelines recommend stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) in medically inoperable patients. There are excellent outcome and toxicity data for SBRT of peripheral lung tumors. However, the discussion on SBRT for centrally located tumors...
Autores principales: | Roesch, J., Panje, C., Sterzing, F., Mantel, F., Nestle, U., Andratschke, N., Guckenberger, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135810/ https://www.ncbi.nlm.nih.gov/pubmed/27912764 http://dx.doi.org/10.1186/s13014-016-0732-5 |
Ejemplares similares
-
Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours – a clinical physics perspective
por: Lambrecht, Marie, et al.
Publicado: (2016) -
Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC
por: Arnett, Andrea L.H., et al.
Publicado: (2019) -
Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study
por: Basler, L., et al.
Publicado: (2018) -
Dosimetric analysis of 17 cardiac Sub-structures, Toxicity, and survival in ultra central lung tumor patients treated with SBRT
por: Ahmadsei, Maiwand, et al.
Publicado: (2023) -
Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
por: Repka, Michael C., et al.
Publicado: (2017)